# Agilent Technologies Moat

Status: published. Policy: company-analysis-1.

Agilent has a qualified narrow moat from laboratory workflow integration and diagnostics equipment relationships tied to continuing reagent shipments. These disclosures support repeat demand and some switching friction, but do not establish exclusivity or quantify switching costs. Targeted price increases benefited results across several years, demonstrating pricing power. Intense competition, continuing innovation requirements and uneven cost absorption limit demonstrated durability.

## switching_costs

Diagnostics equipment leases linked to reagent shipments create continuing customer relationships. Integrated instruments, consumables and software, alongside overlapping instrument and service customers, support workflow switching friction. The friction is an inference from disclosed arrangements, not a measured switching cost or exclusive purchasing obligation.

Durability: The reagent-linked leasing model is disclosed in both 2023 and 2025. Its persistence supports an established advantage, although lease lengths, renewal outcomes and its share of company revenue are undisclosed. Realized targeted price increases reinforce the economic evidence.

Risks: Named instrument and diagnostics competitors compete intensely. Vendor-neutral services limit any inference of proprietary ecosystem lock-in, while customer order cancellations and technological change constrain protection. Actual 2025 margin compression shows incomplete cost absorption despite price increases.

Invalidation: The thesis would weaken materially if reagent shipments and service demand persistently declined relative to the installed base, lease renewals deteriorated, customers routinely substituted competing consumables without workflow disruption, or price increases repeatedly required concessions or caused customer losses.

Competitors: Leica Biosystems, Inc., Roche Ventana Medical Systems, Inc., Thermo Fisher Scientific Inc., Shimadzu Corporation, Waters Corporation, Danaher Corporation
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm) · 2025-12-22
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087226000064/a-20260731.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087226000064/a-20260731.htm) · 2026-09-01
- [https://www.sec.gov/Archives/edgar/data/1090872/000119312526040286/a-20260203.htm](https://www.sec.gov/Archives/edgar/data/1090872/000119312526040286/a-20260203.htm) · 2026-02-06
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087224000049/a-20241031.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087224000049/a-20241031.htm) · 2024-12-20
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087223000020/a-20231031.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087223000020/a-20231031.htm) · 2023-12-20
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087226000055/a-20260430.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087226000055/a-20260430.htm) · 2026-06-01
- [https://earray.chem.agilent.com/earray/pages/common/Terms.jsp](https://earray.chem.agilent.com/earray/pages/common/Terms.jsp) · 2026-10-18
- [https://www.sec.gov/Archives/edgar/data/1090872/000119312526384426/a-ex99_1.htm](https://www.sec.gov/Archives/edgar/data/1090872/000119312526384426/a-ex99_1.htm) · 2026-09-08
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087226000062/exhibit991-q326pressrelease.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087226000062/exhibit991-q326pressrelease.htm) · 2026-08-26
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087226000052/exhibit991-q226pressrelease.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087226000052/exhibit991-q226pressrelease.htm) · 2026-05-27

[JSON](https://beanvest.com/stock/a/moat.json)